Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by PWIB123on Sep 19, 2022 4:10pm
120 Views
Post# 34972111

RE:RE:RE:RE:RE:RE:RE:I give up

RE:RE:RE:RE:RE:RE:RE:I give upJust slightly under the sadness barometer of the divorce situation is the fact that one divorce situation can effectively tank the stock value to a 52 week low.  THTX has got to be in tune with how bad they've let the stock bleed out and never allow themselves in this position again.  A lot of shares were offloaded today, so hopefully that was the last of it.  

SPCEO1 wrote: There is a good chance the selling we have seen both recently and today has to do with a divorce situation and has nothing to do with the company at all. I know the couple who are divorcing and their holdings of THTX are caught up in the divorce. I can't be sure this is the issue but there is a decent chance some of the recent selling is related to that. They had a sizable position in the stock and likely they have been selling it in recent months.

Meanwhile, THTX is likley on the verge of sharing what should be important news about their  phase 1b trial. We can't yet know how important it may be, whether it will be good or bad news or when exactly they will choose to share it. But  we can know they do have important info about TH-1902 right now as many of the early patients have completed 12 weeks on the drug. THTX's recent behavior hints that there is good news forthcoming on TH-1902 on some level.

Don't let an unfortunate divorce situtation which is impacting the stock's price make you think something bad is going on at THTX because that is not likely the case - just the opposite is more likely. 


Biobob wrote: Bucknelly is 100% right on that one.. the IR person sounds like an answering machine.. an insult to the kind of discussion large and long term shareholder should have not with IR but with CEO.  And yes they delivered nothing that translated and in anything for shareholders.  I am deeply disapointed in our last ditch effort to bring this company to another level.  It as been a mistake to hire Paul Mme Chairwomen.  Unfortunatly it was our last chance at it in my book.




<< Previous
Bullboard Posts
Next >>